Zenas BioPharma, Inc. (ZBIO)

Market Cap	1.34B
Revenue (ttm)	15.00M
Net Income (ttm)	-177.01M
Shares Out	42.11M
EPS (ttm)	-5.31
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,137,049
Open	28.00
Previous Close	23.90
Day's Range	24.20 - 34.33
52-Week Range	5.83 - 34.33
Beta	n/a
Analysts	Strong Buy
Price Target	33.80 (+6.29%)
Earnings Date	Nov 11, 2025

About ZBIO

Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc?RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus. The company also develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated a...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Sep 13, 2024
• Employees: 130
• Stock Exchange: NASDAQ
• Ticker Symbol: ZBIO
• Website: https://zenasbio.com

Financial Performance

In 2024, Zenas BioPharma's revenue was $5.00 million, a decrease of -90.00% compared to the previous year's $50.00 million. Losses were -$156.99 million, 322.9% more than in 2023.

Analyst Summary

According to 5 analysts, the average rating for ZBIO stock is "Strong Buy." The 12-month stock price target is $33.8, which is an increase of 6.29% from the latest price.

Price Target

$33.8

(6.29% upside)

Analyst Consensus: Strong Buy